Uncategorized

Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter

Admin • CCON • 2/2/2016

Chau T. Dang, Anthony F. Yu, Lee W. Jones, Jennifer Liu, Richard M. Steingart, Daniel F. Argolo, Larry Norton and Clifford A. Hudis Journal of Clinical Oncology Published online before print. February 1, 2016, doi:10.1200/JCO.2015.64.5515JCO February 1, 2016 JCO645515 Read Article

Stem Cell Theranostics and CapellaBio Announce Cardio-Oncology Collaboration and Discovery of a Novel Class of Cardioprotective Drug Therapies

Admin • CCON • 12/16/2015

REDWOOD CITY, Calif. and PALO ALTO, Calif., Dec. 16, 2015 /PRNewswire/ — Stem Cell Theranostics (SCT) and CapellaBio announced today that they have established a cardio-oncology collaboration to discover novel drug therapies to prevent... Read more »

Mixed Results for Herceptin Cardiotoxicity Prevention

Admin • CCON • 12/10/2015

Neither a beta-blocker nor an angiotensin-converting enzyme (ACE) inhibitor, used as prophylaxis against trastuzumab’s (Herceptin) adverse cardiac effects, successfully prevented left ventricle remodelling in breast cancer patients in a randomized... Read more »

Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer

Admin • CCON • 12/9/2015

SAN ANTONIO, TX—Results from the MANTICORE trial include prophylactic use of standard heart failure (HF) pharmacotherapy prevents trastuzumab-associated left ventricular ejection fraction (LVEF) and reduces treatment interruptions due to left... Read more »

Can cancer itself damage the heart?

Admin • CCON • 12/3/2015

Research presented today at EuroEcho-Imaging 2015 raises the possibility that cancer itself may damage heart muscle irrespective of exposure to cancer drug therapies. Researchers from the UK’s first dedicated cardio-oncology... Read more »

Harwich Port woman blindsided by chemotherapy

Admin • CCON • 11/29/2015

Breast cancer was a devastating diagnosis for Kathleen Mingle, a teacher who played tennis, ran and generally led an active and fit life. But the shock was compounded when she... Read more »

CCC 2015: Improving Cardiac Care for Cancer Patients

Admin • CCON • 11/19/2015

CCS Position Statement Dr. Dent, co-founder of the Ottawa Cardiology-Oncology Clinic at The Ottawa Hospital, led the session presenting the Canada Cardiovascular Society’s (CCS) first position statement on cardiovascular complications... Read more »

NIH Funding Opportunity: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)

Admin • CCON • 11/17/2015

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to... Read more »

AHA: Candesartan May Preserve Cardiac Function in Breast Ca Patients

Admin • CCON • 11/11/2015

ORLANDO — An angiotensin II receptor blocker may help to preserve cardiac function in patients receiving treatment for breast cancer, according to results of a small trial reported here. Read... Read more »

Heart drugs during breast cancer treatment can help women avoid cardiac issues

Admin • CCON • 11/11/2015

ORLANDO, Fla. — Many cancer treatments have a dark side — they can damage the heart. New research suggests this risk might be lowered in women with breast tumors if... Read more »